Drugs / Calaspargase Pegol
Calaspargase Pegol
also known as
Calaspargase pegol-mknl · Asparlas · Calaspargasa pegol · EZN-2285 · SC-PEG · SC-PEG E. coli L-asparaginase
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ASPARLAS | — | 2018-12-20 | fda.gov ↗ |
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03719105 | Mar 2019 → Dec 2027 expected | aggressive NK-cell leukemia | New York Medical College | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT05581030 | May 2023 → Oct 2026 expected | acute lymphoblastic leukemia | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT05034627 | Aug 2022 → Dec 2025 overdue | pancreatic adenocarcinoma | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04953780 | Sep 2021 → Dec 2025 overdue | acute myeloid leukemia | West Virginia University | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06561074 | Sep 2025 → Dec 2029 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06317662 | Jun 2025 → Dec 2028 expected | B-cell acute lymphoblastic leukemia, acute leukemia of ambiguous lineage | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04817761 | Jul 2021 → Mar 2025 | acute lymphoblastic leukemia | Servier | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03007147 | Aug 2017 → Sep 2027 expected | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00671034 | Jul 2008 → Feb 2011 | B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01225874 | Dec 1999 → Mar 2006 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
Also used as a comparator or background therapy in 15 trials
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calaspargase Pegol | “Patients in this arm were randomized to receive IV Calaspargase Pegol (SC-PEG) 2500 IU/m2, administered as a single dose during induction and for 30 weeks post-induction.” NCT01574274 ↗ |
| Known as | Asparlas | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108728 ↗ |
| Known as | Calaspargasa pegol | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108728 ↗ |
| Known as | Calaspargase pegol-mknl | “During Cycle 1, participants will receive prednisone, vincristine, pegaspargase/calaspargase pegol-mknL, and daunorubicin.” NCT05326516 ↗ |
| Known as | EZN-2285 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108728 ↗ |
| Known as | SC-PEG | “Patients in this arm were randomized to receive IV Calaspargase Pegol (SC-PEG) 2500 IU/m2, administered as a single dose during induction and for 30 weeks post-induction.” NCT01574274 ↗ |
| Known as | SC-PEG E. coli L-asparaginase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01225874 ↗ |
| Modality | Protein / enzyme biologic | “SC-PEG E. Coli L-asparaginase” NCT00671034 ↗ |
| Route | Intravenous | “Given IV” NCT00671034 ↗ |